Regeneron Pharmaceuticals, Inc. – LSE:0R2M.L
Regeneron Pharmaceuticals stock price today
Regeneron Pharmaceuticals stock price monthly change
Regeneron Pharmaceuticals stock price quarterly change
Regeneron Pharmaceuticals stock price yearly change
Regeneron Pharmaceuticals key metrics
Market Cap | 77.31B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 36.11 |
Revenue | 13.10B |
EBITDA | 4.45B |
Income | 3.85B |
Revenue Q/Q | -0.54% |
Revenue Y/Y | 5.90% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 33.99% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRegeneron Pharmaceuticals stock price history
Regeneron Pharmaceuticals stock forecast
Regeneron Pharmaceuticals financial statements
| Jun 2023 | 3.15B | 968.4M | 30.66% |
|---|---|---|---|
| Sep 2023 | 3.36B | 1.00B | 29.97% |
| Dec 2023 | 3.43B | 1.15B | 33.77% |
| Mar 2024 | 3.14B | 722M | 22.96% |
| Mar 2024 | 3.14B | 722M | 22.96% |
|---|---|---|---|
| Sep 2025 | 2.49B | 1.43B | 57.61% |
| Oct 2025 | 3.73B | 1.41B | 37.78% |
| Dec 2025 | 3.89B | 1.21B | 31.34% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 30657500000 | 6.63B | 21.66% |
|---|---|---|---|
| Sep 2023 | 32163300000 | 7.25B | 22.57% |
| Dec 2023 | 33080200000 | 7.10B | 21.48% |
| Mar 2024 | 34369600000 | 7.37B | 21.47% |
| Jun 2023 | 1.02B | -2.38B | -614.2M |
|---|---|---|---|
| Sep 2023 | 1.11B | -496.3M | -407.3M |
| Dec 2023 | 1.08B | -66.2M | -446.1M |
| Mar 2024 | 1.51B | -1.68B | 47.1M |
Regeneron Pharmaceuticals alternative data
| Aug 2023 | 12,099 |
|---|---|
| Sep 2023 | 12,256 |
| Oct 2023 | 12,256 |
| Nov 2023 | 12,256 |
| Dec 2023 | 12,463 |
| Jan 2024 | 12,463 |
| Feb 2024 | 12,463 |
| Mar 2024 | 13,450 |
| Apr 2024 | 13,450 |
| May 2024 | 13,450 |
| Jun 2024 | 13,677 |
| Jul 2024 | 13,677 |
Regeneron Pharmaceuticals other data
| Patent |
|---|
Application Filling date: 5 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 31 Mar 2022 Issue date: 8 Sep 2022 |
Application Filling date: 28 Feb 2022 Issue date: 8 Sep 2022 |
Application Filling date: 24 Jul 2020 Issue date: 8 Sep 2022 |
Application Filling date: 17 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 17 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 13 Jan 2022 Issue date: 1 Sep 2022 |
Application Filling date: 4 May 2022 Issue date: 25 Aug 2022 |
Grant Utility: Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formation Filling date: 12 Jun 2019 Issue date: 23 Aug 2022 |
Application Filling date: 2 May 2022 Issue date: 18 Aug 2022 |
| Insider | Compensation |
|---|---|
| Dr. Leonard S. Schleifer (1953) Co-Founder, Pres, Chief Executive Officer & Executive Director | $4,770,000 |
Dr. George D. Yancopoulos (1960) Co-Founder, Pres & Chief Scientific Officer & Director | $3,980,000 |
| Mr. Robert E. Landry Jr. (1964) Executive Vice President of Fin. & Chief Financial Officer | $1,560,000 |
| Mr. Daniel P. Van Plew (1973) Executive Vice President and GM of Industrial Operations & Product Supply | $1,460,000 |
Dr. Andrew J. Murphy (1958) Executive Vice President of Research | $1,290,000 |
Ms. Patrice Gilooly Senior Vice President of Quality Assurance & Operations | |
Ms. Beth F. Levine Senior Vice President, Associate Gen. Counsel & Chief Compliance Officer | |
| Mr. Joseph J. LaRosa Executive Vice President, Gen. Counsel & Sec. | |
Mr. Gerald Underwood Senior Vice President of Technical Operations | |
Justin Holko Vice President of Investor Relations |
-
What's the price of Regeneron Pharmaceuticals stock today?
One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $627.13.
-
When is Regeneron Pharmaceuticals's next earnings date?
Unfortunately, Regeneron Pharmaceuticals's (0R2M.L) next earnings date is currently unknown.
-
Does Regeneron Pharmaceuticals pay dividends?
No, Regeneron Pharmaceuticals does not pay dividends.
-
How much money does Regeneron Pharmaceuticals make?
Regeneron Pharmaceuticals has a market capitalization of 77.31B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 7.76% to 13.12B US dollars.
-
What is Regeneron Pharmaceuticals's stock symbol?
Regeneron Pharmaceuticals, Inc. is traded on the LSE under the ticker symbol "0R2M.L".
-
What is Regeneron Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Regeneron Pharmaceuticals?
Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Regeneron Pharmaceuticals's key executives?
Regeneron Pharmaceuticals's management team includes the following people:
- Dr. Leonard S. Schleifer Co-Founder, Pres, Chief Executive Officer & Executive Director(age: 72, pay: $4,770,000)
- Dr. George D. Yancopoulos Co-Founder, Pres & Chief Scientific Officer & Director(age: 65, pay: $3,980,000)
- Mr. Robert E. Landry Jr. Executive Vice President of Fin. & Chief Financial Officer(age: 61, pay: $1,560,000)
- Mr. Daniel P. Van Plew Executive Vice President and GM of Industrial Operations & Product Supply(age: 52, pay: $1,460,000)
- Dr. Andrew J. Murphy Executive Vice President of Research(age: 67, pay: $1,290,000)
- Ms. Patrice Gilooly Senior Vice President of Quality Assurance & Operations
- Ms. Beth F. Levine Senior Vice President, Associate Gen. Counsel & Chief Compliance Officer
- Mr. Joseph J. LaRosa Executive Vice President, Gen. Counsel & Sec.
- Mr. Gerald Underwood Senior Vice President of Technical Operations
- Justin Holko Vice President of Investor Relations
-
Is Regeneron Pharmaceuticals founder-led company?
Yes, Regeneron Pharmaceuticals is a company led by its founders Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos.
-
How many employees does Regeneron Pharmaceuticals have?
As Jul 2024, Regeneron Pharmaceuticals employs 13,677 workers, which is 2% more then previous quarter.
-
When Regeneron Pharmaceuticals went public?
Regeneron Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 5 Nov 2014.
-
What is Regeneron Pharmaceuticals's official website?
The official website for Regeneron Pharmaceuticals is regeneron.com.
-
Where are Regeneron Pharmaceuticals's headquarters?
Regeneron Pharmaceuticals is headquartered at 777 Old Saw Mill River Road, Tarrytown, NY.
-
How can i contact Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals's mailing address is 777 Old Saw Mill River Road, Tarrytown, NY and company can be reached via phone at +91 48477000.
Regeneron Pharmaceuticals company profile:
Regeneron Pharmaceuticals, Inc.
regeneron.comLSE
14,165
Medical - Pharmaceuticals
Healthcare
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Tarrytown, NY 10591-6707
:
ISIN: US75886F1075
:
